• Home
• About Us
• Lead Consultants
• Services
• Contact Us
• Site Map

Dr. Thomas Chase has over 50 years experience in the discovery and clinical development of new drugs for CNS disease, first at the National Institutes of Health (NIH) and then as President and CEO of Hamilton Pharmaceuticals, Chase Pharmaceuticals, Riverside Pharnaceuticals and most recently of Chase Therapeutics. He is a graduate of the Sloan School of Management at the Massachusetts Institute of Technology and of the School of Medicine at Yale University. He completed neurology residency training at Harvard Medical School and the Massachusetts General Hospital.

Dr. Chase then received postdoctoral training in basic and clinical neuropharmacology at the National Institute of Mental Health (NIMH) before transferring to the National Institute of Neurological Disorders and Stroke (NINDS). While at the NINDS, Dr. Chase served as Scientific Director, Intramural Director, Clinical Director and founding Chief of the Experimental Therapeutics Branch. He received both the Superior and the Distinguished Service Medals from the U.S. Public Health Service as well as awards from Yale University and the Johann Wolfgang Goethe Universitat of Frankfurt, the American Parkinson's Disease Association, National Parkinson Foundation, American Academy of Neurology, Movement Disorders Society, and the governments of Bolivia and Pakistan. Dr. Chase’s research has focused on the pathogenesis and treatment of Parkinson's and Alzheimer's disease and related neuropsychiatric disorders. He served as principal investigator on nearly 200 clinical trials, published 500 peer-reviewed papers and served as co-inventor of more than 150 patents issued or pending. Dr. Chase contributed to the development of several major drugs used in the treatment of brain disorders including Sinemet and Sinemet-CR, apomorphine, amantadine, Rotigotine, and Rytary.

Ms. Francis joined KM in June 2007. She received a BA in Biology and Psychology from Norfolk State University in 1988 and MSc. in Project Management from the George Washington University in 2003. She has over 35 years of clinical development experience in the US, Europe and Asia. Ms. Francis has an extensive knowledge of Good Clinical Practices and the Code of Federal Regulations required for product development. She has worked for both Government and Industry and for both the Sponsor and Contract Research Organizations. Her vast experience is widespread across a variety of indications some of which include; Women’s Health, Central Nervous System, Stroke, Infectious Disease, Blood Products, Oncology, and Gene Transfer. She has a comprehensive knowledge of the requirements for Global clinical development planning and conduct for drugs and biologics for Phase 1, 2, and 3 clinical studies. Her excellent communication skills have proven to be very effective while acting as liaison between clients and CROs, sites, vendors and the FDA to ensure well-conducted studies. Her formal Project Management training has been invaluable in the oversight of timelines and budgets. Her philosophy is to always be “audit ready”. Ms. Francis is well respected and well connected within the industry.

Ms. Feranil has more than 20 years of experience in the development of drugs and biologics. She has extensive experience in the preparation and management of regulatory submissions to FDA and to Health Canada. Ms. Feranil’s experience with IND/NDA products includes neurology, psychiatry, oncology, ophthalmology, and dental products with a special interest in orphan (rare) diseases. Ms. Feranil is well versed in the Code of Federal Regulations and guidance documents. Ms. Feranil acts as the regulatory agent for various Sponsors and has been involved in numerous FDA-Sponsor meetings.

Ms. Feranil received a BA in Biology from the University of Virginia in 2000. Prior to joining KM in April 2008, Ms. Feranil worked at Prestwick Pharmaceuticals, Inc. for more than 7 years.